Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Topically Delivered Tumor Necrosis Factor-Ī±-Targeted Gene Regulation forĀ Psoriasis.

Lewandowski KT, Thiede R, Guido N, Daniel WL, Kang R, Guerrero-Zayas MI, Seeger MA, Wang XQ, Giljohann DA, Paller AS.

J Invest Dermatol. 2017 Sep;137(9):2027-2030. doi: 10.1016/j.jid.2017.04.027. Epub 2017 May 11. No abstract available.

2.

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH.

Genes Dev. 2015 Apr 1;29(7):732-45. doi: 10.1101/gad.257394.114.

3.

Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH.

Sci Transl Med. 2013 Oct 30;5(209):209ra152. doi: 10.1126/scitranslmed.3006839.

4.

Scanometric microRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates.

Alhasan AH, Kim DY, Daniel WL, Watson E, Meeks JJ, Thaxton CS, Mirkin CA.

Anal Chem. 2012 May 1;84(9):4153-60. doi: 10.1021/ac3004055. Epub 2012 Apr 10.

5.

Multiplexed nanoflares: mRNA detection in live cells.

Prigodich AE, Randeria PS, Briley WE, Kim NJ, Daniel WL, Giljohann DA, Mirkin CA.

Anal Chem. 2012 Feb 21;84(4):2062-6. doi: 10.1021/ac202648w. Epub 2012 Jan 30.

6.

Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles.

Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA.

Bioconjug Chem. 2010 Dec 15;21(12):2250-6. doi: 10.1021/bc1002423. Epub 2010 Nov 11.

7.

Tailoring DNA structure to increase target hybridization kinetics on surfaces.

Prigodich AE, Lee OS, Daniel WL, Seferos DS, Schatz GC, Mirkin CA.

J Am Chem Soc. 2010 Aug 11;132(31):10638-41. doi: 10.1021/ja104859j. Erratum in: J Am Chem Soc. 2010 Nov 17;132(45):16296.

8.

Gold nanoparticles for biology and medicine.

Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA.

Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3280-94. doi: 10.1002/anie.200904359. Review.

9.

Colorimetric Cu(2+) detection using DNA-modified gold-nanoparticle aggregates as probes and click chemistry.

Xu X, Daniel WL, Wei W, Mirkin CA.

Small. 2010 Mar 8;6(5):623-6. doi: 10.1002/smll.200901691. No abstract available.

10.

Bioluminescent nanosensors for protease detection based upon gold nanoparticle-luciferase conjugates.

Kim YP, Daniel WL, Xia Z, Xie H, Mirkin CA, Rao J.

Chem Commun (Camb). 2010 Jan 7;46(1):76-8. doi: 10.1039/b915612g. Epub 2009 Oct 12.

11.

Microarray-based multiplexed scanometric immunoassay for protein cancer markers using gold nanoparticle probes.

Kim D, Daniel WL, Mirkin CA.

Anal Chem. 2009 Nov 1;81(21):9183-7. doi: 10.1021/ac9018389.

12.

Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.

Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ.

J Am Chem Soc. 2009 Oct 21;131(41):14652-3. doi: 10.1021/ja9071282. Erratum in: J Am Chem Soc. 2010 Dec 8;132(48):17335. J Am Chem Soc. 2010 Mar 3;132(8):2845.

13.

Multiplexed protein arrays enabled by polymer pen lithography: addressing the inking challenge.

Zheng Z, Daniel WL, Giam LR, Huo F, Senesi AJ, Zheng G, Mirkin CA.

Angew Chem Int Ed Engl. 2009;48(41):7626-9. doi: 10.1002/anie.200902649. No abstract available.

14.

Colorimetric nitrite and nitrate detection with gold nanoparticle probes and kinetic end points.

Daniel WL, Han MS, Lee JS, Mirkin CA.

J Am Chem Soc. 2009 May 13;131(18):6362-3. doi: 10.1021/ja901609k.

PMID:
19368386
15.

Templated spherical high density lipoprotein nanoparticles.

Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA.

J Am Chem Soc. 2009 Feb 4;131(4):1384-5. doi: 10.1021/ja808856z.

16.

A new approach to amplified telomerase detection with polyvalent oligonucleotide nanoparticle conjugates.

Zheng G, Daniel WL, Mirkin CA.

J Am Chem Soc. 2008 Jul 30;130(30):9644-5. doi: 10.1021/ja803035p. Epub 2008 Jul 3.

PMID:
18597453
17.

Comparative biochemistry of a cytosolic artiodactyl glycosidase.

Cygan J, Neufeld-Kaiser W, Jara G, Daniel WL.

Comp Biochem Physiol B Biochem Mol Biol. 1997 Apr;116(4):437-46.

PMID:
9149397
18.

Diet-disease interactions at the molecular level: an experimental paradigm.

Kaput J, Swartz D, Paisley E, Mangian H, Daniel WL, Visek WJ.

J Nutr. 1994 Aug;124(8 Suppl):1296S-1305S. doi: 10.1093/jn/124.suppl_8.1296S. Review.

PMID:
7914920
19.

The basics of genetic disease.

Daniel WL.

Compr Ther. 1992 Apr;18(4):6-12. Review.

PMID:
1628484
20.

Characterization of arylsulfatase C isozymes from human liver and placenta.

Shankaran R, Ameen M, Daniel WL, Davidson RG, Chang PL.

Biochim Biophys Acta. 1991 Jun 24;1078(2):251-7.

PMID:
2065092
21.

Comparative biochemistry of mammalian arylsulfatase C and steroid sulfatase.

Ruoff BM, Daniel WL.

Comp Biochem Physiol B. 1991;98(2-3):313-22.

PMID:
1873987
22.
23.
24.
25.

Comparative biochemistry of mammalian arylsulfatases A and B.

Thompson DB, Daniel WL.

Comp Biochem Physiol B. 1988;90(4):823-31.

PMID:
2907871
26.

Arylsulfatase B synthesis and clearance in inbred mouse strains.

Daniel WL.

Experientia. 1987 Dec 1;43(11-12):1209-11.

PMID:
3691739
27.

Isolation and characterization of rat hepatic ascorbic acid-2-sulfatases.

Thompson DB, Daniel WL.

Enzyme. 1987;37(3):134-40.

PMID:
2884099
28.

Mammalian arylsulfatases A and B: relative rates of hydrolysis of artificial substrates.

Thompson DB, Daniel WL.

Experientia. 1986 Feb 15;42(2):150-1.

PMID:
2868913
29.

Purification and properties of arylsulfatase B from high- and low-activity mouse strains.

Daniel WL, Ruoff BM, Thompson DB, Gore JB.

Biochem Genet. 1985 Oct;23(9-10):771-86.

PMID:
4084217
30.

Linkage of loci affecting a murine liver protein and arylsulfatase B to chromosome 13.

Elliott RW, Daniel WL, Taylor BA, Novak EK.

J Hered. 1985 Jul-Aug;76(4):243-6.

PMID:
4031460
31.

Arylsulfatase C and the steroid sulfatases.

Daniel WL.

Isozymes Curr Top Biol Med Res. 1985;12:189-228. Review. No abstract available.

PMID:
3886594
32.

Comparative studies of rodent anionic arylsulfatases.

Thompson DB, Daniel WL, Glaser JH.

Comp Biochem Physiol B. 1985;82(1):55-61.

PMID:
2865044
33.

Genetic analysis of murine arylsulfatase C and steroid sulfatase.

Keinanen BM, Nelson K, Daniel WL, Roque JM.

Genetics. 1983 Sep;105(1):191-206.

34.

Murine arylsulfatase C: evidence for two isozymes.

Nelson K, Keinanen BM, Daniel WL.

Experientia. 1983 Jul 15;39(7):740-2.

PMID:
6574927
35.

Comparative studies of murine anionic and cationic arylsulfatase B (1).

Harrison BW, Daniel WL, Abbas KJ.

Experientia. 1982 Jan 15;38(1):73-5.

PMID:
6120093
36.

Genetic regulation of murine hepatic arylsulfatase B activity during development.

Daniel WL, Harrison BW, Nelson K.

J Hered. 1982 Jan-Feb;73(1):24-8.

PMID:
7069188
37.

Murine liver arylsulfatase B processing influenced by region on chromosome 17.

Daniel WL, Womack JE, Henthorn PS.

Biochem Genet. 1981 Apr;19(3-4):211-25.

PMID:
7247931
38.

Trisomy 10p produced by recombination involving maternal inversion inv(10)(pllq26).

Lansky-Shafer SC, Daniel WL, Ruiz L.

J Med Genet. 1981 Feb;18(1):59-61.

39.

Comparative biochemistry of murine arylsulfatase B.

Daniel WL, Caplan MS.

Biochem Genet. 1980 Aug;18(7-8):625-42.

PMID:
7470017
40.

Murine arylsulfatase B: evidence favoring control of liver and kidney activity by two regulatory elements.

Daniel WL, Abedin K, Langelan RE.

J Hered. 1980 May-Jun;71(3):161-7.

PMID:
7391540
41.

Interstrain variation of murine arylsulfatase C.

Nelson K, Daniel WL.

Experientia. 1979 Mar 15;35(3):309-10.

PMID:
446599
42.
43.

Genetic study of infantile spasm with hypsarrhythmia.

Fleiszar KA, Daniel WL, Imrey PB.

Epilepsia. 1977 Mar;18(1):55-62.

PMID:
870317
44.
45.

Genetic control of heat sensitivity and activity level of murine arylsulfatase B.

Daniel WL.

Biochem Genet. 1976 Dec;14(11-12):1003-18.

PMID:
1016219
46.

Absence of brain ganglioside abnormalities in shambling mutant mice.

Seyfried TN, Weber EJ, Daniel WL.

J Neurochem. 1976 Jul;27(1):295-6. No abstract available.

PMID:
956836
47.

Genetics of murine liver and kidney arysulfatase b.

Daniel WL.

Genetics. 1976 Mar 25;82(3):477-91.

48.

Traumatic dislocation of the first metatarsophalangeal joint. A case report.

Daniel WL, Beck EL, Duggar GE, Bennett AJ.

J Am Podiatry Assoc. 1976 Feb;66(2):97-100. No abstract available.

PMID:
1245732
49.

Effects of cystic fibrosis sera on Proteus vulgaris motility.

Cohen FL, Daniel WL.

J Med Genet. 1974 Sep;11(3):253-6. No abstract available.

50.

Mental retardation associated with an unusual amino acid excretion pattern.

Daniel WL, Tosi T.

Clin Genet. 1974;6(1):60-5. No abstract available.

PMID:
4426131

Supplemental Content

Loading ...
Support Center